Session Type: Abstract Submissions (ACR)
Data on over-10-years drug survival of TNF inhibitors (TNFi) are still lacking. The aim of the study is to analysed the long-term retention rate of the first TNFi and to compare the drug survival of infliximab (IFX), etanercept (ETN) and adalimumab (ADA) for the treatment of rheumatoid arthritis (RA) in a setting of real-life.
We extracted data from a local registry that includes all RA patients (all fulfilling ACR/EULAR 2010 classification criteria) treated with biologic therapies between October 1999 and May 2014 in our Rheumatology Unit, limiting the analysis to patients treated with IFX, ETN, or ADA as first-line biologic drug. Data were collected through 31 May 2014. Drug survival up to 12-year follow-up was evaluated overall by the Kaplan-Meier method and compared according to anti-TNF agent after matching for propensity scores (based on age, sex, health assessment questionnaire [HAQ], disease duration, concomitant DMARDs therapy, concomitant corticosteroids, Disease Activity Score 28 [DAS28], ESR and CRP) by a stratified logrank test.
The analysis included 583 patients (mean age [±SD]=54 [±12.4] years, mean disease duration 8.6 [±18.9] years), treated with IFX (n=222), ADA (n=182), or ETN (n=179). The median time of receiving TNFi was 44.3 months and the overall 5-years and 12-years TNFi retention rates were 44.1% and 19.39%, respectively. Drug inefficacy (51.1%) and toxicity (41.2%) represented the main causes of treatment discontinuation. Combination with MTX was significantly associated with a higher TNFi retention rate (p<0.01). ETN showed a significant lower probability of discontinuation compared with both IFX (z=6.52, p<0.0001) and ADA (z=5.66, p<0.0001). No significant differences emerged between IFX and ADA (z=0.19, p=0.85).
In a real-life setting, the 12-years retention rate of the first TNFi was lower than 20% and the most frequent reason for discontinuation was inefficacy (51.1%). The drug survival of ETN was significantly higher compared with anti-TNF monoclonal antibodies.
E. G. Favalli,
A. E. Penatti,
P. L. Meroni,
« Back to 2014 ACR/ARHP Annual Meeting
ACR Meeting Abstracts - https://acrabstracts.org/abstract/the-12-years-retention-rate-of-the-first-line-tnf-inhibitor-in-the-treatment-of-rheumatoid-arthritis-real-life-data-from-a-local-registry/